BioWorld

Jan. 9, 2006

How Leukemia Cells Rule Neighbors: With Iron Fist

Millennium's CEO Pledges Still More Velcade Growth

KAI's PKC Program Nabs $340M Deal With Sankyo

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today) Read More

Tioga's Series A Round: $24M For Phase IIb Trial Of IBS Drug

Today's news in brief

BioWorld

BioWorld briefs for Feb. 12, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

BioWorld

Jan. 9, 2006

How Leukemia Cells Rule Neighbors: With Iron Fist

Millennium's CEO Pledges Still More Velcade Growth

Other News To Note

Appointments And Advancements

KAI's PKC Program Nabs $340M Deal With Sankyo

Tioga's Series A Round: $24M For Phase IIb Trial Of IBS Drug

Today's news in brief

SCAN is core circuit affected in Parkinson’s disease

Astellas’ ASP-2246 shows promise in stroke management

TL1A is overexpressed in hidradenitis suppurativa

News in brief